Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea

Br J Clin Pharmacol. 2012 Jan;73(1):140-3. doi: 10.1111/j.1365-2125.2011.04048.x.

Abstract

Aim: We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection.

Methods: Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment.

Results: The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002).

Conclusions: Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
  • 2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects
  • Adult
  • Amoxicillin / administration & dosage*
  • Amoxicillin / adverse effects
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Clarithromycin / administration & dosage*
  • Clarithromycin / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / adverse effects
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects*
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Proton Pump Inhibitors
  • Republic of Korea
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Lansoprazole
  • Amoxicillin
  • Clarithromycin